100% Pharma Tariffs and Section 232: Inside the Trump 2026 Tariff Strategy

President Donald Trump’s tariff agenda entered a new phase in April 2026 with the announcement of two sweeping Section 232 actions, a pending legal challenge at the US Court of International Trade, and the launch of 76 fresh Section 301 investigations. Taken together, the moves represent the administration’s most aggressive use of trade authority since the Supreme Court struck down the president’s preferred blanket tariff framework in February.

The Section 232 Announcements: Metals and Pharmaceuticals

On April 2, 2026, the White House announced two new sets of tariffs issued under Section 232 of the Trade Expansion Act, which allows the president to impose import restrictions on national security grounds. The first set restructures and partially reduces tariffs on steel, aluminum, and copper, rolling back some of the higher emergency duties that had been layered on during the prior twelve months.

The second set is more consequential for both consumers and global supply chains: tariffs of up to 100% on patented pharmaceutical imports. The measure, which the administration has described as a lever to bring drug production back to the United States, immediately raised concerns among health care analysts, hospital systems, and pharmaceutical companies that import finished drug products and active pharmaceutical ingredients.

According to PIIE analysis published shortly after the announcement, US tariffs now average just over 12% overall, up from approximately 2.5% the day before Trump began his second term on January 20, 2025. That average is down from a temporary peak of roughly 28% reached last year, reflecting the Supreme Court’s February ruling and subsequent partial rollbacks.

The Court Challenge

The legal environment surrounding these tariffs remains fluid. On April 10, 2026, a three-judge panel of the US Court of International Trade in New York heard oral arguments in a case challenging the temporary tariffs the president invoked after the Supreme Court’s February ruling. Plaintiffs in that case include a coalition of importers, small businesses, and at least one state attorney general, arguing that the emergency statute the White House is relying on does not authorize the scope of the current tariff structure.

A ruling is expected within weeks, and analysts expect the losing side to appeal. If the Court of International Trade narrows the administration’s authority, the White House has already signaled it would pivot to additional Section 232 or Section 301 actions rather than let tariff revenue lapse.

76 New Section 301 Investigations

In what appears to be a pre-emptive hedge against the courtroom outcome, the US Trade Representative (USTR) launched 76 new Section 301 investigations in early April. Of those:

  • 60 investigations focus on inadequate foreign enforcement against forced labor.
  • 16 investigations concern what the USTR has termed “structural excess manufacturing capacity,” a phrase most often associated with Chinese state-supported industries.

Section 301, the statute most famously used during the first Trump administration’s 2018-2019 trade confrontation with China, has historically been upheld more readily in court than some of the emergency tariff authorities now under challenge. Trade lawyers have interpreted the 76-investigation rollout as the administration preparing a legally durable fallback if current Section 232 or emergency actions are narrowed.

Who Is Paying

By 2026, US businesses and consumers were covering almost 90% of tariff costs, according to research cited by the Federal Reserve and reported by multiple outlets including Fortune. The economic incidence has fallen most heavily on:

  • Agricultural exporters, who have faced retaliatory measures from trading partners, particularly on soybeans, dairy, and pork.
  • Coastal state economies with high exposure to exports and import-dependent manufacturing.
  • Retail and durable goods consumers, who have seen price pass-through on items ranging from appliances to furniture.

A Fortune analysis published April 14 surveyed economic blows across all 50 states, finding that farmers, exporters, and shoppers alike have absorbed meaningful pricing and volume impacts. The White House, in its 2026 Economic Report released April 13 and covered by the Deseret News, emphasized tariff revenue and reshoring investment announcements while acknowledging transition costs.

The Pharmaceutical Angle

The 100% tariff ceiling on patented pharmaceutical imports is the component drawing the most attention from analysts and industry trade groups. The measure would affect:

  • Branded finished drugs imported from Europe, India, and other major pharmaceutical producers.
  • Active pharmaceutical ingredients, where supply chain concentration in a handful of global producers is well documented.
  • Specialty biologics and advanced therapies with limited domestic manufacturing.

PhRMA and BIO, the two largest industry trade associations, have publicly pushed back on the measure and warned that domestic capacity cannot replace the affected imports on the timeline the tariffs imply. The administration has responded that the tariffs are calibrated to accelerate, not eliminate, the reshoring investments already underway.

Drug pricing experts have pointed out that the tariffs could interact with existing Medicare price negotiation rules and the 340B drug pricing program in complex ways, and that retail prescription pricing could eventually reflect at least a portion of the added costs.

What to Watch Next

Several inflection points loom in the coming weeks:

  • Court of International Trade ruling. The April 10 oral arguments could produce a decision that reshapes the tariff framework within weeks.
  • Implementation timing on pharma tariffs. The White House has not yet published a full schedule of which drug categories face the 100% ceiling versus lower rates.
  • Trading partner responses. The European Union, India, and China have all been consulted on the new measures, and retaliatory announcements in one or more of those markets remain possible.
  • Midterm political environment. With the 2026 midterms approaching, agricultural-state senators of both parties have been vocal about tariff impacts on their constituents.

The Bottom Line

The Trump administration’s tariff strategy in April 2026 is characterized by three simultaneous tracks: invoking Section 232 for sector-specific duties (most notably 100% on patented pharmaceuticals), defending emergency-authority tariffs in court, and pre-positioning 76 Section 301 investigations as a legally durable backup. For consumers and businesses, the immediate implication is that trade costs are unlikely to fall materially in the near term, and that further sector-specific announcements remain a live possibility.

Sources

This article summarizes publicly reported policy developments, legal filings, and economic research. It is for informational purposes only and does not constitute investment, tax, legal, or financial advice.